Malin backs another microbiome upstart as Artizan breaks out of ‘covert’ role
The hot R&D field centering on the microbiome has spawned yet another biotech upstart
Artizan Biosciences, a spinout from the lab of Yale’s Richard Flavell, has emerged from a brief covert stint under the radar with two prominent backers and a plan to tackle inflammatory bowel disease as its first of many targets.
Based in Durham, NC with labs in New Haven, CT, Artizan is helmed by James Rosen, a former InterSouth partner who had handled VC investments for the Bill & Melinda Gates Foundation. Malin says it bagged a 32% equity stake in Artizan after joining Hatteras Venture Partners in a Series A.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.